A rare case of orbital hodgkin lymphoma demonstrating therapeutic response to a novel systemic medication

Brynn N Wajda; Michael P Rabinowitz

doi:10.1080/01676830.2016.1243133

A rare case of orbital hodgkin lymphoma demonstrating therapeutic response to a novel systemic medication

Orbit. 2017 Feb;36(1):52-54. doi: 10.1080/01676830.2016.1243133. Epub 2016 Nov 8.

Authors

Brynn N Wajda¹, Michael P Rabinowitz²

Affiliations

¹ a Ophthalmology Residency Program , Wills Eye Hospital, Thomas Jefferson University Hospital , Philadelphia , Pennsylvania , USA.
² b Department of Oculoplastic and Orbital Surgery , Wills Eye Hospital , Philadelphia , Pennsylvania , USA.

PMID: 27824517
DOI: 10.1080/01676830.2016.1243133

Abstract

Orbital Hodgkin lymphoma is infrequent, representing less than 1% of adult orbital malignancies. It is typically seen in the setting of terminally advanced systemic disease. This case highlights orbital, head, and neck disease in a systemically stable individual treated with the novel anti-CD30 monoclonal antibody brentuximab vedotin.

Keywords: Brentuximab; Hodgkin; lymphoma; orbit.

Publication types

Case Reports

MeSH terms

Adult
Biomarkers, Tumor / metabolism
Brentuximab Vedotin
Hodgkin Disease / diagnosis
Hodgkin Disease / drug therapy*
Hodgkin Disease / metabolism
Humans
Immunoconjugates / therapeutic use*
Magnetic Resonance Imaging
Male
Orbital Neoplasms / diagnosis
Orbital Neoplasms / drug therapy*
Orbital Neoplasms / metabolism

Substances

Biomarkers, Tumor
Immunoconjugates
Brentuximab Vedotin